Quick Takeaways: Why It Matters? Dechra’s Boston HQ move and community-facing strategy signal how veterinary pharma is increasingly aligning with mainstream human health and life sciences ecosystems, not just traditional animal-health hubs, which could intensify competition for talent, par...
Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
Quick Takeaways: Why It Matters? Gelteq’s canine palatability trials with Kemin confirm that its gel-based delivery platform can effectively mask bitter compounds and deliver strong acceptance across multiple flavor profiles, even with naturally unpalatable ingredients. This is a key enabl...
Quick Takeaways: Why It Matters? Cronus Pharma is bringing price competition to a key canine heart failure drug class by launching the first FDA‑approved bioequivalent chewable to Vetmedin, available nationwide through vet distributors. For the market, this should lo...
Quick Takeaways: Why It Matters? Viyash is using BioForLife as a front-end platform to scale its companion animal business in Europe, starting with Italy, one of the continent’s largest and fastest-growing pet health markets. Market-wise, the all-cash ...
Quick Takeaways Why It Matters? Parnell strengthens its position in the controlled veterinary injectables segment, gaining preference among practices prioritizing safety-differentiated euthanasia agents. Visual dye innovation reduces medication errors, accelerating adopti...
Quick Takeaways: Why It Matters? Lenivia strengthens Zoetis’ lead in monoclonal antibody–based pain management for dogs by adding a longer-acting OA option to its portfolio. Market-wise, a single injection providing up to three months of osteoarthritis pain...
Quick Takeaways Why It Matters? A new proprietary CNS asset from Orion, exclusively commercialized by Zoetis in the US, that taps into fast‑growing demand for medical management of canine anxiety and should expand the addressable market beyond situational noise phobia toward mo...
Quick Takeaways Why It Matters? Ceva is using this JV to turn Japan from a peripheral presence into a true platform market, bolting its global livestock and pet portfolio onto Bussan Animal Health’s 75‑year brand, field force, and ~€40M business to create a full‑line ...
Quick Takeaways: Why It Matters? Elanco is moving fast to become the “go‑to” screwworm partner for U.S. regulators and producers, adding Negasunt Powder and Tanidil to its toolkit via FDA Emergency Use Authorization and an EPA Section 18 emergency exemption ...
